Nav: Home

Center for Infectious Disease Research, Fred Hutch: Success in humans with malaria vaccine

January 04, 2017

Jan. 4, 2017 (Seattle, Washington) -- A clinical trial with human volunteers has found that a next-generation malaria vaccine that uses genetically attenuated parasites shows a favorable safety profile, is well tolerated and stimulates an appropriate immune response, according to a study published today in Science Translational Medicine by scientists at the Center for Infectious Disease Research (CIDR) and Fred Hutchinson Cancer Research Center.

Malaria is caused by Plasmodium parasites that are transmitted to humans by a mosquito bite and first infects the liver and then the blood, leading to over 200 million infections and nearly a half-million deaths worldwide in 2015. While control measures, such as insecticide-treated bed nets and antimalarial drugs, are making headway against the disease, it is generally accepted that an effective vaccine will be required to completely eliminate malaria.

With this new vaccine candidate, CIDR and Fred Hutch are at the forefront of malaria vaccine design.

The new study describes the use of a genetically engineered malaria parasite that is weakened by removal of three specific genes that are required for the parasite to successfully infect and cause disease in humans. These genetically attenuated parasites, or "GAPs", are incapable of multiplying in the human liver, but are alive and effectively stimulate the immune system to build up defenses that can protect against a real malaria infection.

'Attenuation' is a commonly used strategy for making vaccines and has been used for viral and bacterial vaccines dating back to Edward Jenner's very first vaccine against smallpox. However, attenuation in most previous vaccines was achieved by growing the virus or bacteria in culture for long periods of time until the organisms lost some of their virulence, or by using a highly related but non-pathogenic organism. The GAP malaria vaccine was instead created using precise genetic engineering of the malaria parasite and is a unique approach in combating parasitic diseases.

"This most recent publication builds on our previous work," said Sebastian Mikolajczak, Ph.D., CIDR Principal Scientist and GAP project leader. "We had already good indicators in preclinical studies that this new 'triple knock-out' GAP (GAP3KO), which has three genes removed, is completely attenuated. The clinical study now shows that the GAP3KO vaccine is completely attenuated in humans and also shows that even after only a single administration, it elicits a robust immune response against the malaria parasite. Together these findings are critical milestones for malaria vaccine development"

"This report is a major advance in malaria vaccine development by providing the first evidence that genetically attenuated Plasmodium falciparum parasites are safe and immunogenic in humans," said Robert Seder, M.D., Chief of Cellular Immunology at the Vaccine Research Center at the National Institutes of Health. "Future studies demonstrating protective efficacy will be the next critical milestone for continued development of this promising vaccine approach". Seder was not involved in the study.

The GAP3KO trial was conducted at the CIDR Human Challenge Center, which is part of the Seattle Malaria Clinical Trials Center, an inter-institutional collaboration that includes CIDR and Fred Hutch, among others, in an effort to combat malaria through clinical trials of candidate vaccines and drugs.

"We are very fortunate to have the human malaria challenge model to take the critical next step evaluating the efficacy of GAP3KO in preventing malaria in people," said James Kublin, M.D., M.P.H., the Medical Director of the Seattle MCTC and a Fred Hutch scientist. "The Hutch is looking forward to bringing its expertise in clinical trial design and management to the next stage of tests for this vaccine. The collaborations we have with CIDR and other nearby institutions is what makes Seattle a world leader in the malaria vaccine development and the human challenge model."
-end-
ABOUT THE CENTER FOR INFECTIOUS DISEASE RESEARCH

CIDR is the largest independent, non-profit organization in the U.S. focused solely on infectious disease research. Our research is the foundation for new drugs, vaccines and diagnostics that benefit those who need our help most: the fourteen million who will otherwise die each year from infectious diseases, including malaria, HIV/AIDS and tuberculosis. Founded in 1976, the Center partners with key collaborators around the globe and strives to make discoveries that will save lives. For more information, visit http://www.cidresearch.org.

ABOUT FRED HUTCH

At Fred Hutchinson Cancer Research Center, home to three Nobel laureates, interdisciplinary teams of world-renowned scientists seek new and innovative ways to prevent, diagnose and treat cancer, HIV/AIDS and other life-threatening diseases. Fred Hutch's pioneering work in bone marrow transplantation led to the development of immunotherapy, which harnesses the power of the immune system to treat cancer with minimal side effects. An independent, nonprofit research institute based in Seattle, Fred Hutch houses the nation's first and largest cancer prevention research program, as well as the clinical coordinating center of the Women's Health Initiative and the international headquarters of the HIV Vaccine Trials Network. Private contributions are essential for enabling Fred Hutch scientists to explore novel research opportunities that lead to important medical breakthroughs. For more information visit fredhutch.org or follow Fred Hutch on Facebook, Twitter or YouTube.

MEDIA CONTACTS

Jacque Seaman
Center for Infectious Disease Research
206.838.92912
jseaman@feareygroup.com

Jonathan Rabinovitz
Fred Hutchinson Cancer Research Center
206.667.6906
206.658.7612
jrabinov@fredhutch.org

The Fearey Group

Related Malaria Articles:

Breakthrough in malaria research
An international scientific consortium led by the cell biologists Volker Heussler from the University of Bern and Oliver Billker from the Umeå University in Sweden has for the first time systematically investigated the genome of the malaria parasite Plasmodium throughout its life cycle in a large-scale experiment.
Scientists close in on malaria vaccine
Scientists have taken another big step forward towards developing a vaccine that's effective against the most severe forms of malaria.
New tool in fight against malaria
Modifying a class of molecules originally developed to treat the skin disease psoriasis could lead to a new malaria drug that is effective against malaria parasites resistant to currently available drugs.
Malaria expert warns of need for malaria drug to treat severe cases in US
The US each year sees more than 1,500 cases of malaria, and currently there is limited access to an intravenously administered (IV) drug needed for the more serious cases.
Monkey malaria breakthrough offers cure for relapsing malaria
A breakthrough in monkey malaria research by two University of Otago scientists could help scientists diagnose and treat a relapsing form of human malaria.
Getting to zero malaria cases in zanzibar
New research led by the Johns Hopkins Center for Communication Programs, Ifakara Health Institute and the Zanzibar Malaria Elimination Program suggests that a better understanding of human behavior at night -- when malaria mosquitoes are biting -- could be key to preventing lingering cases.
Widely used malaria treatment to prevent malaria in pregnant women
A global team of researchers, led by a research team at the Liverpool School of Tropical Medicine (LSTM), are calling for a review of drug-based strategies used to prevent malaria infections in pregnant women, in areas where there is widespread resistance to existing antimalarial medicines.
Protection against Malaria: A matter of balance
A balanced production of pro and anti-inflammatory cytokines at two years of age protects against clinical malaria in early childhood, according to a study led by ISGlobal, an institution supported by ''la Caixa'' Foundation.
The math of malaria
A new mathematical model for malaria shows how competition between parasite strains within a human host reduces the odds of drug resistance developing in a high-transmission setting.
Free malaria tests coupled with diagnosis-dependent vouchers for over-the-counter malaria treatment
Coupling free diagnostic tests for malaria with discounts on artemisinin combination therapy (ACT) when malaria is diagnosed can improve the rational use of ACTs and boost testing rates, according to a cluster-randomized trial published this week in PLOS Medicine by Wendy Prudhomme O'Meara of Duke University, USA, and colleagues.
More Malaria News and Malaria Current Events

Top Science Podcasts

We have hand picked the top science podcasts of 2019.
Now Playing: TED Radio Hour

In & Out Of Love
We think of love as a mysterious, unknowable force. Something that happens to us. But what if we could control it? This hour, TED speakers on whether we can decide to fall in — and out of — love. Guests include writer Mandy Len Catron, biological anthropologist Helen Fisher, musician Dessa, One Love CEO Katie Hood, and psychologist Guy Winch.
Now Playing: Science for the People

#542 Climate Doomsday
Have you heard? Climate change. We did it. And it's bad. It's going to be worse. We are already suffering the effects of it in many ways. How should we TALK about the dangers we are facing, though? Should we get people good and scared? Or give them hope? Or both? Host Bethany Brookshire talks with David Wallace-Wells and Sheril Kirschenbaum to find out. This episode is hosted by Bethany Brookshire, science writer from Science News. Related links: Why Climate Disasters Might Not Boost Public Engagement on Climate Change on The New York Times by Andrew Revkin The other kind...
Now Playing: Radiolab

An Announcement from Radiolab